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Summary 
The Gram positive bacterium Streptococcus pyogenes (group A streptococcus; GAS) is 
the major etiological agent of a variety of skin and mucosal infections in humans. 
Whilst the majority of GAS infection results in only mild, uncomplicated disease, the 
migration of GAS from superficial to deep tissue sites can result in invasive infection. 
In recent years, there has been a resurgence in severe GAS disease, however, the details 
of GAS pathogenesis have yet to be fully elucidated. Increasingly, subversion of the 
host plasminogen activation system is being implicated in the virulence of S. pyogenes. 
GAS display receptors for the human zymogen plasminogen on the cell surface, one of 
which is the plasminogen-binding group A streptococcal M-like protein (PAM). PAM 
has been implicated in the pathogenesis of certain GAS isolates, but the mechanism of 
plasminogen binding by PAM, and the role of this interaction in the pathogenesis of 
GAS, requires further investigation. Thus, the focus of this thesis has been to 
characterise plasminogen binding by PAM and a number of naturally occurring PAM 
variants. 
 
Characterisation of PAM genes from 13 GAS isolates revealed that whilst these 
molecules are highly conserved in the c and d repeat domains, they display significant 
variation within the plasminogen binding repeat motifs (a1/a2). Percent identity to the 
prototype PAM a1/a2 repeat sequence ranged from 52% to 100% amongst the variants 
studied here. No correlation was seen between the presence of a PAM gene, or variation 
within the sequence of PAM, and site of GAS isolation. In order to determine the 
impact of sequence variation on protein function, recombinant proteins representing six 
naturally occurring variants of PAM, together with a recombinant M1 protein were 
expressed and purified. Equilibrium dissociation constants for the interaction of PAM 
 
 xii
variants with biotinylated glu-plasminogen ranged from 1.58 nM to 7.58 nM. Effective 
concentrations of prototype PAM required for 50% inhibition of plasminogen binding to 
immobilised PAM variants ranged from 0.34 nM to 22.06 nM. These results suggest 
that while variation in the a1/a2 region of the PAM protein does affect the comparative 
affinity of PAM variants, the functional capacity to bind plasminogen at physiologically 
relevant concentrations is conserved. Additionally, a potential role for the a1 region of 
PAM in eliciting a protective immune response was investigated using a mouse model 
for GAS infection. The a1 region of PAM was found to protect immunised mice 
challenged with a homologous PAM-positive GAS strain. These data suggest a link 
between selective immune pressure against the plasminogen-binding repeats and the 
functional conservation of the binding domain in PAM variants. 
 
Site-directed mutagenesis of full length PAMNS13 protein from an invasive GAS isolate 
was undertaken to assess the contribution of residues in the a1 and a2 repeat domains to 
plasminogen binding function. Mutagenesis to alanine of key plasminogen binding site 
lysine residues in the a1 and a2 repeats (Lys98 and Lys111) did not abrogate plasminogen 
binding by PAM, nor did additional mutagenesis of Arg101, His102 and Glu104, which 
have previously been implicated in plasminogen binding by PAM. Plasminogen binding 
was only abolished with the additional mutagenesis of Arg114 and His115 to alanine. 
Furthermore, mutagenesis of both arginine (Arg101 and Arg114) and histidine (His102 and 
His115) residues abolished interaction with plasminogen despite the presence of Lys98 
and Lys111 in the binding repeats. This study shows for the first time that residues 
Arg101, Arg114, His102 and His115 in both the a1 and a2 repeat domains of PAM can 
mediate high affinity plasminogen binding. These data suggest that highly conserved 
arginine and histidine residues may compensate for variation elsewhere in the a1 and a2 
 
 xiii
plasminogen binding repeats, and may explain the maintenance of high affinity 
plasminogen binding by naturally occurring variants of PAM. 
 
Initial sequence characterisation of PAM variants in this study revealed a 
phylogenetically distinct PAM variant, PAMNS88.2.  This variant binds plasminogen with 
high affinity (Kd  = 7.58 nM), despite displaying only 52% identity to the classical a1/a2 
repeat domain of PAM. It was therefore of interest to characterise the putative 
plasminogen binding domain of PAMNS88.2. Additionally, the association of GAS strain 
NS88.2, from which PAMNS88.2 was isolated, with the invasive disease bacteraemia, 
makes it a candidate for virulence studies employing the recently developed human 
plasminogen transgenic mouse. Site-directed mutagenesis of the putative plasminogen 
binding site indicated that as with PAMNS13, PAMNS88.2 does not interact with 
plasminogen exclusively via lysine residues. Mutagenesis to alanine of lysine residues 
Lys96 and Lys101 reduced but did not abrogate plasminogen binding by PAMNS88.2. 
Plasminogen binding was only abolished with the additional mutagenesis of Arg107 and 
His108 to alanine. Furthermore, mutagenesis of Arg107 and His108 abolished plasminogen 
binding by PAMNS88.2 despite the presence of Lys96 and Lys101 in the binding site. Given 
that GAS strain NS88.2 is associated with the invasive disease bacteraemia, and is 
virulent in the humanised plasminogen transgenic mouse, the successful abrogation of 
plasminogen binding by PAMNS88.2 may facilitate the development of a PAMNS88.2 
allelic replacement isogenic mutant for use in future studies involving this model.  
 
This study examines in detail the interaction of PAM and PAM variants with the human 
zymogen plasminogen. The maintenance of plasminogen-binding function in spite of 
binding site sequence variation suggests that the ability to interact with plasminogen is 
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evolutionarily advantageous to a subset of GAS isolates. Additionally, this study 
provides previously unreported details of the ability of PAM to interact with 
plasminogen independently of binding site lysine residues. These findings have 
implications for both the future identification of novel plasminogen binding proteins, 
and may facilitate both the understanding of the role of PAM in GAS disease, and the 
development of therapeutics to assist in the treatment and prevention of streptococcal 
infection.
